EFL033 - GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes
Join host Chase Hendrickson, MD, from Vanderbilt University Medical Center as he discusses an article in The Journal of Clinical Endocrinology & Metabolism with Ashok Balasubramanyam, MD, from Baylor…
Read the full articleYou might also wanna read
GLP-1 vs SGLT2: The New Frontier in Diabetes Therapy
A new commentary in The Lancet examines whether oral GLP-1 receptor agonists can match SGLT2 inhibitors in cardiovascular and kidney protect
GLP-1 Receptor Agonists and Eye Safety: Examining the NAION Risk at ADA 2025
Do their associations with nonarteritic anterior ischemic optic neuropathy and other adverse outcomes make these drugs more risky than benef
mdsc.pe·15h agoOral diabetes drug orforglipron shows superior blood sugar control in phase 3 trial
The GLP-1 receptor agonist outperformed dapagliflozin on glycaemic endpoints, though tolerability concerns persist.
Exploring GLP-1 Receptor Agonists for Neurodegeneration - Part 2
In part two of this two-part series, Dr. Vikram Karnik and Dr. Lorraine Kalia discuss the preclinical data and epidemiological data that led
GLP-1 Initiation Did Not Improve Insulin Discontinuation Rates Among Veterans with Type 2 Diabetes
A target trial emulation found that adding glucagon-like peptide-1 receptor agonists (GLP-1RAs) to basal insulin therapy for type 2 diabetes
GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation
Conditions : Alzheimer Disease; Diabetes Mellitus Type 2; Obesity & Overweight Interventions : Drug: GLP-1 Receptor Agonists; Drug: DPP-4 In
Comments
Sign in to join the conversation.
No comments yet. Be the first.